<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-01-20">20 January 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Hagen</forename><forename type="middle">Sjard</forename><surname>Bachmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pharmacogenetics</orgName>
								<orgName type="institution">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Werner</forename><surname>Meier</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">Evangelisches Krankenhaus Duesseldorf</orgName>
								<address>
									<settlement>Dusseldorf</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Du Bois</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Gynecology and Gynecologic Oncology</orgName>
								<orgName type="institution">Klinikum Essen Mitte</orgName>
								<address>
									<settlement>Essen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rainer</forename><surname>Kimmig</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><forename type="middle">Dominik</forename><surname>Kuhlmann</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Gynecology and Obstetrics</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<settlement>Dresden</settlement>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Dresden and German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Winfried</forename><surname>Siffert</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pharmacogenetics</orgName>
								<orgName type="institution">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jalid</forename><surname>Sehouli</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">Charité Medical University of Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kerstin</forename><surname>Wollschlaeger</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">University of Magdeburg</orgName>
								<address>
									<settlement>Magdeburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jens</forename><surname>Huober</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">University of Ulm</orgName>
								<address>
									<settlement>Ulm</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Hillemanns</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">Medical University of Hannover</orgName>
								<address>
									<settlement>Hannover</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Burges</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">Klinikum Großhadern</orgName>
								<address>
									<settlement>Munich</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Barbara</forename><surname>Schmalfeldt</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">Klinikum rechts der Isar, Munich</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Behnaz</forename><surname>Aminossadati</surname></persName>
							<affiliation key="aff12">
								<orgName type="laboratory">Coordinating Centre for Clinical Trials (KKS)</orgName>
								<orgName type="institution">Philipps University of Marburg</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Professor</roleName><forename type="first">Pauline</forename><surname>Wimberger</surname></persName>
							<email>pauline.wimberger@uniklinikum-dresden.de</email>
							<affiliation key="aff3">
								<orgName type="department">Department of Gynecology and Obstetrics</orgName>
								<orgName type="institution">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Gynecology and Obstetrics</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<settlement>Dresden</settlement>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Dresden and German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Department of Gynecology and Obstetrics</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<addrLine>Fetscherstraße 74</addrLine>
									<postCode>D-01307</postCode>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-01-20">20 January 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">3420C2828D4CCC2AC0AB4661ED6B684A</idno>
					<idno type="DOI">10.1111/bcp.12688</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:18+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>farnesyltransferase inhibitor</term>
					<term>lonafarnib</term>
					<term>ovarian cancer</term>
					<term>rs11623866</term>
					<term>single nucleotide polymorphism</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Despite promising preclinical findings regarding clinical utility of farnesyltransferase inhibitors (FTI), such as lonafarnib, success of clinical trials is limited.</s><s>A multicentre AGO-OVAR-15 phase II trial reported an unfavourable effect of lonafarnib on the outcome of patients with advanced ovarian cancer.</s><s>This study was performed as a genetic subgroup analysis of the AGO-OVAR-15 trial, and investigated the utility of the promoter polymorphism rs11623866 of the farnesyltransferase ß-subunit gene (FNTB) in predicting the clinical effectiveness of lonafarnib.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p><s>The influence of rs11623866 (c.-609G &gt; C) on FNTB promoter activity was investigated by electrophoretic-mobility-shift assay, luciferase-reporter assay and RT-qPCR.</s><s>A total of 57 out of 105 patients from the AGO-OVAR-15 trial, treated with carboplatin and paclitaxel ± lonafarnib, was genotyped for rs11623866 by restriction fragment length</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>• Farnesyltransferase inhibitors, such as lonafarnib, have failed to demonstrate clinical benefit in ovarian cancer • Even an adverse effect of this drug was reported in the AGO-OVAR-15 trial.</s><s>• We investigated the utility of the farnesyltransferase ß-subunit (FNTB) promoter polymorphism rs11623866 in predicting the clinical effect of lonafarnib.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Ovarian cancer is the leading cause of death among women with gynaecologic malignancies <ref type="bibr" target="#b0">[1]</ref>.</s><s>Standard treatment of ovarian cancer constitutes primary radical surgery, aiming at macroscopically complete tumour resection and subsequent platinum-and paclitaxel-based chemotherapy <ref type="bibr" target="#b1">[2]</ref>.</s><s>Residual tumour burden after primary surgery is believed to be one of the most relevant prognostic factors for ovarian malignancies <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>.</s><s>Advanced ovarian cancer is usually chemotherapy sensitive with an overall clinical response rate of 70-80% <ref type="bibr" target="#b4">[5]</ref>.</s><s>However, despite this profound sensitivity to platinum-based chemotherapy and despite continuous attempts to implement maintenance therapies, more than 50% of all patients experience recurrence, resulting in a poor overall prognosis <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s><s>Therefore, the development of targeted therapy strategies is highly desirable.</s><s>In this context, there are recent advances in the administration of anti-angiogenetic monoclonal antibodies (e.g.</s><s>bevacizumab) or tyrosine kinase inhibitors (e.g.</s><s>pazopanib) for targeted ovarian cancer therapy <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</s><s>However, presently, no predictive biomarkers are available for these kinds of therapies.</s><s>Apart from this, farnesyltransferase inhibitors (FTI), such as lonafarnib, have also been of significant clinical interest.</s><s>The FTI lonafarnib abrogates lipid modification of H-Ras and other farnesylation-dependent proteins, such as Rheb, RhoB or centromer-associated motor proteins, thereby interfering with tumourigenic signalling <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>.</s><s>Preclinical results showed that lonafarnib, either as single agent or in combination with taxanes, is active not only in a broad spectrum of tumour cell lines in vitro but also in human ovarian cancer and breast cancer animal models <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref>.</s><s>Due to these encouraging results, a variety of clinical studies investigated the effect of lonafarnib in different cancer entities.</s><s>However, the majority of trials failed to demonstrate any substantial clinical benefit of lonafarnib.</s><s>Consequently, the concept of targeting farnesyltransferase activity has not entered clinical practice <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>.</s><s>In a randomized clinical trial (AGO-OVAR-15, phase II), we recently analyzed the potential clinical benefit of carboplatin and paclitaxel with or without lonafarnib in first line treatment of epithelial ovarian cancer International Federation of Gynaecology and Obstetrics (FIGO) stages IIB-IV.</s><s>This clinical trial comprised 105 patients and did not resolve any significant difference in the nonlonafarnib-treated vs. the lonafarnib-treated arm, with regard to progression free survival (PFS) and overall survival (OS).</s><s>In contrast, lonafarnib treatment appeared to exert a negative effect upon survival, since significant inferiority of the lonafarnib-treated arm was reported in a stratum with residual tumour of more than 1 cm or the presence of distant metastasis (FIGO IV) <ref type="bibr" target="#b17">[18]</ref>.</s></p><p><s>So far, farnesyltransferase expression level has been discussed as a potential predictive biomarker for lonafarnib response <ref type="bibr" target="#b19">[19]</ref>.</s><s>However, little is known about transcriptional regulation of farnesyltransferases and how this relates to lonafarnib effectiveness <ref type="bibr" target="#b20">[20]</ref>.</s><s>We previously demonstrated prognostic relevance of FNTBpromoter core polymorphisms in several cancer entities, such as breast or renal cell cancer <ref type="bibr" target="#b21">[21]</ref>.</s><s>Of those, rs11623866 (c.-609G &gt; C) was the only SNP with a sufficient minor allele frequency for analysis in a limited patient cohort and was in linkage disequilibrium to the other FNTB promoter SNPs with lower allele frequency and in silico analysis predicted its potential functionality.</s></p><p><s>Therefore, we genotyped a subgroup of patients from the AGO-OVAR-15 clinical trial and investigated, in terms of an exploratory genetic study, whether the candidate FNTB promoter polymorphism rs11623866 i) influences farnesyltransferase expression and ii) may be a predictive</s></p><p><s>• It shows that the adverse effect of lonafarnib is limited to patients carrying a rs11623866 GG genotype.</s><s>No effect was observed for the other genotypes.</s><s>• Our results encourage retrospective evaluation of FNTB polymorphisms in previous FTI-studies, especially those, reporting a positive FTI response.</s></p><p><s>biomarker for the effect of lonafarnib in ovarian cancer patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient characteristics</head><p><s>The current study was based on the recent AGO-OVAR-15, phase II clinical trial (EudraCT number: 2004-004515-26), comprising 105 patients.</s><s>This trial compared standard chemotherapy (carboplatin and paclitaxel) with or without lonafarnib in primary advanced ovarian cancer.</s><s>Patients above 18 years with histologically confirmed FIGO stages IIB to IV ovarian cancer were included.</s><s>They had undergone previous debulking surgery (with the aim of macroscopic complete tumour resection) within 6 weeks before random assignment had been eligible.</s><s>Lonafarnib was administered at a dose of 100 mg orally twice a day during chemotherapy and was increased thereafter to 200 mg twice a day, up to 6 months as a maintenance therapy.</s><s>Maintenance therapy was administered for a maximum of 6 months.</s><s>Patients were stratified according to residual tumour size and FIGO stage <ref type="bibr" target="#b17">[18]</ref>.</s><s>Stratum 1 consisted of patients with FIGO IIB to IIIC and a residual tumour up to 1 cm and stratum 2 consisted of patients with FIGO stage IV and/or a residual tumour of more than 1 cm.</s><s>In an amendment of the existing approval for the AGO-OVAR-15 trial, we investigated whether rs11623866 could be a predictive biomarker for the effect of lonafarnib.</s><s>This amendment was approved by the ethics committee, when the AGO-OVAR-15 trial had already started (Ethikkommission der Ärztekammer Nordrhein, Düsseldorf, reference number: 2004-004515-26 / 2005276 / 10-066) and was performed in accordance with good clinical practice guidelines, national laws and the Declaration of Helsinki.</s><s>To prevent a systematic bias due to selection of long-living patients, we recruited also those patients with available DNA that already died (as suggested by the local ethics committee and in accordance with the declaration of the Central Ethics Committee of Germany <ref type="bibr" target="#b22">[22]</ref>.</s><s>In total, DNA samples for genotyping could be obtained from 57 (54.1%) out of 105 participants in the AGO-OVAR-15 (subgroup genetics) trial.</s><s>Clinicopathological data of this subgroup were comparable with those of the complete study group of the AGO-OVAR-15 trial and are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Genotype distributions of both treatment arms were not significantly different (P = 0.132).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Polymorphism retrieval and bioinformatic analyses</head><p><s>We retrieved and analyzed data of about 250 putatively functional genetic variations of the FNTB gene region (5' upstream region, 5'UTR, coding region, exon-intron boundaries and 3'UTR) from NCBI dbSNP <ref type="bibr" target="#b23">[23]</ref> and the 1000 Genome browser <ref type="bibr" target="#b24">[24]</ref>.</s><s>Variations with a minor allele frequency (MAF) of at least 0.01 (1%) in Caucasians were considered to be polymorphisms according to the common definition <ref type="bibr" target="#b25">[25]</ref>.</s><s>To locate the core promoter region we performed promoter analysis using PromoterInspector and Gene2Promoter <ref type="bibr" target="#b26">[26]</ref>.</s><s>Analysis of putative rs11623866 allele-dependent binding sites of transcription factors was performed with MatInspector <ref type="bibr" target="#b27">[27]</ref>, Consite <ref type="bibr" target="#b28">[28]</ref> and Alibaba2.1 <ref type="bibr" target="#b29">[29]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DNA preparation and determination of FNTB rs11623866 genotypes</head><p><s>For rs11623866 genotyping, DNA was extracted from whole blood or routinely processed paraffin-embedded tissue.</s><s>Dewaxing and isolation of genomic DNA were done following the manufacturer's instructions using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).</s><s>For polymerase chain reaction (PCR) the Taq DNA Polymerase Master Mix RED (Ampliqon, Herlev, Denmark) was used.</s><s>Genotypes of the rs11623866 polymorphism were determined by restriction fragment length polymorphism analyses using the 'slowdown' PCR <ref type="bibr" target="#b30">[30]</ref>.</s><s>The PCR was performed with the following primers: forward: 5'-GCGGACTGACTGTCTATTT-3', reverse: 5'-GACGCCGTCTCAGTATCA -3' resulting in a PCR product of 140 bp.</s><s>Amplified fragments were digested with restriction enzyme RsaI (New England Biolabs, Beverly, MA, USA) by incubating for 4 h at 37 °C.</s><s>RsaI specifically cuts PCR products that carry the G allele (101 + 39 bp).</s><s>Adequate negative and positive controls were routinely used to ascertain correct genotyping.</s><s>Accuracy of genotyping was additionally validated by direct sequencing of 20 randomly selected samples.</s><s>This revealed complete concordance with the previous results obtained by PCR product digestion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Electrophoretic mobility shift assay (EMSA)</head><p><s>Nuclear extracts of the SKOV-3 ovarian cancer cell line were prepared using the NuCLEAR Extraction Kit (Sigma, Deisenhofen, Germany), according to the manufacturer's instructions.</s><s>Sequences of unlabelled and DY-682 fluorescence-labeled oligonucleotides (Eurofins MWG Operon, Ebersberg, Germany) of the double-stranded DNA probes used were as follows: 5'-ATCCTTGTTCCTT (G/C)TACTGCATTTCAG-3' and 5'-CTGAAATGCAGTA(C/G) AAGGAACAAGGAT-3'.</s><s>EMSAs were performed in triplicate and were carried out with the EMSA buffer kit (Li-COR Bioscience, Lincoln, NE, USA) according to the manufacturer's instructions.</s><s>Double-stranded DNA probes and SKOV3 nuclear extracts (5 μg) were incubated with 2 μl of 10% binding buffer, 2.5 mm DTT, 0.25% Tween-20, 1 μg of poly (dI-dC) and 0.05% NP-40 in a total volume of 20 μl for 30 min at room temperature and separated by electrophoresis on a 6% polyacrylamide gel in 0.5% Tris-borate-EDTA running buffer.</s><s>The gels were scanned by direct infrared fluorescence detection on the Odyssey imaging system (Li-COR Bioscience, Lincoln, NE, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Luciferase reporter assay</head><p><s>The promoter region of FNTB, comprising either the G allele or the C allele, was PCR-amplified from genomic DNA and cloned into the pGEM-T Easy vector (Promega, Madison, WI, USA).</s><s>The amplified promoter region was restricted from the pGEM-T Easy vector and cloned upstream of the firefly luciferase coding region into the pGL4.10 vector (Promega, Madison, WI, USA).</s><s>SKOV3 and A2780 cells were plated into 96-well plates at a density of 1,5 × 10 4 cells/well in 100 μl of Dulbecco's modified eagle medium and Roswell Park Memorial Institute medium, respectively, with 10% fetal bovine serum.</s><s>After 24 h, co-transfections were carried out in 50 μl of medium without serum using 150 ng of the respective pGL4 reporter construct and 50 ng of Renilla luciferase control vector (pGL4.74,</s><s>Promega, Madison, WI, USA) containing 0.5 μl of Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) per transfection according to the manufacturer's instructions.</s><s>After 6 h, the transfection mix was removed and cells were incubated with new medium.</s><s>Twenty-four h after treatment, cells were harvested and assayed for Firefly and Renilla luciferase activities using the Dual-Glo Luciferase Assay System (Promega, Madison, WI, USA) on a Lumat LB 9501 Luminometer (Berthold, Bad Wildbad, Germany).</s><s>To correct for variable transfection efficiency Firefly luciferase activity was normalized to Renilla luciferase activity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RT-qPCR</head><p><s>Total RNA was extracted from snap-frozen samples retrieved from the University Hospital of Essen, Germany, utilizing the Qiagen RNeasy kit according to the manufacturer's instructions.</s><s>One μg of total RNA was applied for cDNA synthesis with oligo dT primers (Roche, Mannheim, Germany) and Superscript II reverse transcriptase (Invitrogen, Karlsruhe, Germany).</s><s>In order to quantify FNTB mRNA levels, we utilized the QuantiTect SYBR Green PCR kit (Qiagen, Hilden, Germany).</s><s>Primer sequences for FNTB transcript detection were designed in order to amplify a region near the translation initiation site (160 bp), spanning exon 1 and exon 2 (forward: 5' CTT CTC CGA GTT CTT TCA, reverse: 5' ATC TTT TCT TCT ACT TTT GC).</s><s>All experimental steps were performed according to the manufacturer's instructions.</s><s>Quantitative RT-qPCR was performed using the ABI-7500 system (Applied Biosystems, Darmstadt, Germany).</s><s>The Cqthreshold was adjusted to a fluorescent level above the background signal and within the linear range of each amplification plot.</s><s>Melting curves were drawn after each PCR run in order to ensure that a single and specific PCRproduct was generated.</s><s>All samples, including non-RT (without reverse transcriptase) and no-template controls were assayed in triplicate.</s><s>Mean Cq values and deviations between the triplicates were calculated.</s><s>Samples with a deviation &gt; 0.5 or with any evidence for melting curve abnormality were repeated.</s><s>In order to allow across sample comparison, FTNB expression was normalized to human beta actin (ACTB) expression as a reference gene <ref type="bibr" target="#b31">[31]</ref>.</s><s>Relative expression values were calculated as following: 2 -[Cq(FNTB) -Cq(ACTB)] .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Clinical variables and genotypes were compared using either Student's t-test, linear anova for continuous variables or Pearson's χ 2 test for categorical data.</s><s>Control for deviation from the Hardy-Weinberg equilibrium was conducted using a publically available Hardy-Weinberg equilibrium calculator <ref type="bibr" target="#b32">[32]</ref>.</s><s>Differences with P values &lt;0.05 were regarded as statistically significant.</s><s>All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software, LaJolla, CA, USA) and SPSS software version 21.0 (IBM, Armonk, NY, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effect of lonafarnib in the studied subpopulation</head><p><s>From 57 out of 105 study patients from the AGO-OVAR-15, we could obtain DNA samples for genotyping.</s><s>Kaplan-Meier analysis, comparing PFS and OS of the lonafarnib-treated arm vs. the untreated arm in our genetic analysis is shown in Figure <ref type="figure">1</ref>.</s><s>Curve progression compares with that of the complete study group, as already published <ref type="bibr" target="#b17">[18]</ref>.</s><s>The tendency for a negative effect of lonafarnib treatment on PFS is detectable in the subgroup of the current study as well.</s><s>Furthermore, the lonafarnib-treated arm showed significantly decreased OS (HR 2.178, 95% CI 1.04, 4.46, P = 0.041).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genetic variability of the FNTB gene locus and in silico analysis of rs11623866</head><p><s>Because the FNTB promoter region is not characterized, we used in silico prediction to determine size and localization of the core promoter region.</s><s>According to this analysis, the core promoter region is located within the first 834 bp 5'upstream of the translation start point.</s></p><p><s>Therefore, we analyzed all genetic variants within 1000 bp 5'upstream of the translation start point as well as all variants located in other putatively functional regions of the FNTB gene, i.e. 5'UTR, exons, exon intron boundaries and 3'UTR.</s><s>Although databases list about 250 genetic variants within these regions, only eight of them reach a MAF of at least 1% in Caucasians (Figure <ref type="figure" target="#fig_0">2A</ref>).</s><s>Three polymorphisms are located within the putative core promoter region.</s><s>One polymorphism is a synonymous single nucleotide polymorphism in exon 10 and two polymorphisms are part of the 3'UTR of FNTB.</s><s>Of those, rs11623866 is the only polymorphism with a sufficient minor allele frequency (38%) for analysis in our limited patient cohort.</s><s>Furthermore, it is in linkage disequilibrium to the other FNTB promoter polymorphisms with lower allele frequencies (data not shown) and in silico analysis predicted its potential functionality due to allele-dependent binding sites of different transcription factors (Figure <ref type="figure" target="#fig_0">2B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genotype-specific binding of SKOV3 nuclear protein to the rs11623866 C allele</head><p><s>We evaluated, whether the rs11623866 polymorphism influences binding of nuclear proteins and may induce differential FNTB promoter activity.</s><s>An EMSA was performed, using SKOV-3 ovarian cancer cell line nuclear extracts (Figure <ref type="figure" target="#fig_0">2C</ref>).</s><s>After incubation with an oligonucleotide probe harbouring the rs11623866 C allele, we observed a distinct band, which was specifically retarded in the presence of a molar excess of a competitor probe but not in the presence of a cross-competitor probe.</s><s>After incubation with a rs11623866 G allele comprising probe, we did not notice any size corresponding band, independently from the presence of any competitor type.</s><s>These findings suggest allele-dependent binding of SKOV-3 nuclear protein, preferentially to the C allele.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Presence of the rs11623866 C allele is associated with impaired FNTB promoter activity in vitro</head><p><s>We subsequently investigated, whether the FNTB rs11623866 G &gt; C polymorphism is associated with differential FNTB promoter activity in vitro.</s><s>Normalized firefly luciferase read-outs of both cell lines revealed reporter activity to be significantly reduced in samples with C allele promoter sequence, compared to G-harbouring promoters (P = 0.0316, P = 0.0404, respectively, Figure <ref type="figure" target="#fig_0">2D</ref>).</s><s>This suggests that the C allele is associated with reduced FNTB promoter activity in vitro.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Presence of the rs11623866 C allele parallels impaired FNTB transcription in vivo</head><p><s>Differential promoter activity, associated with rs11623866 G &gt; C polymorphism, may translate into differential rs11623866 G &gt; C dependent FNTB transcript abundance in vivo.</s><s>To test this assumption, we quantified FNTB</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 1</head><p><s>Survival dependent on treatment arm.</s><s>Kaplan-Meier analysis and the logrank test were used to calculate survival curves representing progression free and overall survival of 57 patients of the AGO-OVAR-15 study dependent on treatment arm.</s><s>TC taxane (paclitaxel) + carboplatin (paclitaxel) ( ).</s><s>LTC lonafarnib + TC ( ) expression in leucocytes from healthy subjects and different rs11623866 G &gt; C genotypes (n = 22, Figure <ref type="figure" target="#fig_0">2E</ref>).</s><s>The GC genotype was significantly associated with decreased FNTB expression, compared with the GG genotype (P = 0.0149).</s><s>In snap-frozen specimens from primary human renal cell or ovarian carcinoma (n = 19, n = 26 respectively), we likewise revealed the presence of the GC as well as the CC genotype to parallel decreased FNTB expression, compared with the presence of the GG genotype.</s><s>However, the difference observed in the ovarian cancer tissues missed statistical significance (P = 0.0421, P = 0.1263, respectively).</s><s>According to these findings we concluded that differential promoter activity, associated with the rs11623866 G &gt; C polymorphism, is accompanied by impaired FNTB transcription in individuals with a GC/CC genotype in normal and malignant tissue.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association of the FNTB rs11623866 G &gt; C polymorphism with the clinical effect of lonafarnib</head><p><s>As reported earlier, the whole study population showed a trend for inferiority of the lonafarnib-treated arm.</s><s>However, for lonafarnib-treated patients with a GG genotype, highly significantly decreased PFS and OS were observed (P &lt; 0.001, P = 0.001, respectively, Figure <ref type="figure" target="#fig_1">3A</ref>).</s><s>Concomitantly, hazard ratios were significantly increased for lonafarnib-treated GG genotype carriers (HR PFS 6.2, P = 0.002; HR OS 9.6, P = 0.006, Table <ref type="table" target="#tab_1">2</ref>).</s><s>Contrarily, for patients with a GC or CC genotype, no significant difference in the survival curves and hazard ratios could be observed between the two study arms (P = 0.919, P = 0.881, P = 0.625, P = 0.538, Table <ref type="table" target="#tab_1">2</ref>, Figure <ref type="figure" target="#fig_1">3B + C</ref>).</s><s>To evaluate further the effect of lonafarnib, we analyzed the toxicities by treatment arm for the subgroup genetics and for GG genotype carriers.</s><s>Distribution and frequency of toxic side effects was comparable with those reported for the complete study population (Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s><s>Especially for GG genotype carriers, the toxicity profile was comparable between the two study arms (Supplementary Table <ref type="table" target="#tab_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The present investigation was performed in association to the AGO-OVAR-15 phase II trial and molecular in vitro and in vivo analysis revealed that the C allele of the FNTB rs11623866 polymorphism was associated with reduced FNTB promoter activity and FNTB mRNA expression compared with the G allele.</s><s>Moreover, the adverse effect of lonafarnib was restricted to patients carrying the homozygous GG genotype.</s></p><p><s>On the basis of promising preclinical data, a variety of clinical trials have been performed to investigate the potential clinical utility of lonafarnib as a targeted therapeutic drug, either as a single agent or in combination with chemotherapy.</s><s>A recent phase II study evaluated the effect of lonafarnib in combination with paclitaxel in a small cohort of patients (n = 33) with resistant non-small cell lung cancer and reported partial response or stable disease in 48% of patients <ref type="bibr" target="#b33">[33]</ref>.</s><s>In contrast, the majority of clinical trials failed to unravel any substantial objective  FNTB polymorphism rs11623866 and the effect of lonafarnib response to lonafarnib administration in, for example, haematological malignancies, head and neck, colorectal or urothelial cancers <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>.</s><s>Due to these discouraging findings, pharmacological inhibition of farnesyltransferase</s></p><p><s>has not yet been translated into clinical practice.</s><s>The present genotyping study was performed in association with the AGO-OVAR-15 phase II trial and evaluated the clinical utility of the FNTB rs11623866 G &gt; C polymorphism as a potential pharmacogenetic predictive biomarker for lonafarnib treatment in ovarian cancer patients.</s><s>Notably, analysis was conducted at a time when it was yet unknown whether or not the enrolled ovarian cancer patients would benefit from the addition of lonafarnib to standard platinum-based chemotherapy.</s><s>As its central finding, AGO-OVAR-15 finally revealed no significant difference in the non-lonafarnib-treated vs. lonafarnib-treated arm.</s><s>Surprisingly, even inferiority in the lonafarnib-treated arm was observed in the stratum with residual tumour of more than 1 cm or the presence of distant metastasis (FIGO IV) <ref type="bibr" target="#b17">[18]</ref>.</s><s>A key finding of the present study was that the adverse effect of lonafarnib was restricted to patients carrying the homozygous GG genotype.</s><s>However, due to the limited number of patients, a further stratification of the subgroup genetics with regard to FIGO stage and residual tumour burden, as conducted in AGO-OVAR-15 <ref type="bibr" target="#b17">[18]</ref>, could not be done.</s><s>At first glance, these findings may appear counterintuitive.</s><s>A straightforward hypothesis would imply that increased expression of a molecular target may favour the success of a related targeted therapy.</s><s>This is demonstrated in, for example, breast cancer patients, in which a correlation between HER2-amplification/overexpression and clinical benefit of trastuzumab (a monoclonal antibody, targeting HER2) is well established <ref type="bibr" target="#b34">[34,</ref><ref type="bibr" target="#b35">35]</ref>.</s><s>However, interestingly, our findings are in line with a recent study, correlating farnesyltransferase mRNA expression level with clinical response to a combination therapy of docetaxel and lonafarnib in patients with therapy refractory solid malignancies.</s><s>In this context, it was reported that patients with lower FNTB baseline expression were more likely to respond to this combination therapy <ref type="bibr" target="#b19">[19]</ref>.</s><s>However, the functional background of this effect remains to be addressed in future studies.</s><s>In this context, we also have to take into consideration that we focused on only one out of a variety of existing SNPs in the FNTB gene.</s><s>Moreover, control of FNTB expression by its promoter sequence may be dependent on the cellular background as well as on the interaction between transcriptional activators and repressors.</s><s>Thus, given our data from EMSA analysis, it may be possible that the nuclear protein fraction, specifically binding the C allele, comprises transcriptional repressor protein(s), which may contribute to negative regulation of FNTB transcription.</s><s>However, in spite of these limitations, the molecular results in our study are indicative that the alleles of the FNTB rs11623866 G &gt; C polymorphism are associated with differential FNTB promoter activity.</s></p><p><s>Conclusively, given the toxicity of lonafarnib <ref type="bibr" target="#b17">[18]</ref> and its limited response among several clinical trials and different cancer entities <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>, the identification of a predictive biomarker for lonafarnib treatment is highly desirable, since there may still exist a subgroup of patients who benefits from this kind of targeted therapy.</s></p><p><s>Notably, our genetic substudy was performed in parallel with the AGO-OVAR-15 main trial, i.e. to a time, when it was not clear yet, whether patients will have clinical benefit from lonafarnib, added to platinum-based chemotherapy.</s><s>Nevertheless, given that rs11623866 enabled a stratification of patients with an adverse effect of lonafarnib, we suppose our study to be a relevant cornerstone, as it implies the general clinical relevance of concomitant and auxiliary SNP analysis among FTI studies as a potential diagnostic tool.</s><s>However, due to the limited number of patients, the present study should be considered exploratory and our results need to be validated in larger patient cohorts.</s><s>Nevertheless, our data provide the rationale to evaluate FNTB polymorphisms systematically in other FTI-studies in a retrospective manner, particularly in those trials where at least partial clinical response has been reported.</s><s>Moreover, apart from the oncological background, it could also be interesting to transfer FNTB polymorphisms analysis, particularly for rs11623866, to other non-oncological diseases, such as chronic hepatitis D or Hutchinson-Gilford progeria syndrome, in which FTIs are candidate drugs of interest <ref type="bibr" target="#b36">[36]</ref><ref type="bibr" target="#b37">[37]</ref><ref type="bibr" target="#b38">[38]</ref>.</s><s>This may help to dissect the mode of action of FTIs, with regard to FNTB promoter activity and possibly to refine a small proportion of patients, in which the presence of a SNP may be indicative for clinical response to FTIs.</s><s>Moreover, since lonafarnib confers an adverse outcome in patients with a GG genotype, our study implies a further rationale to investigate whether those patients may possibly benefit from a therapeutic strategy of farnesyltransferase activation.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2 Functional</head><label>2</label><figDesc><div><p><s>Figure 2 Functional properties of the FNTB G &gt; C polymorphism rs116238662.</s><s>A) Structure of the FNTB gene locus.</s><s>Black boxes represent exons, they are not drawn to scale.</s><s>The 5' and 3'UTR are highlighted in white.</s><s>Positions of FNTB polymorphisms are indicated together with minor allele frequencies given in brackets.</s><s>B) In silico transcription factor binding sites, rs11623866 alleles and the surrounding sequence are shown.</s><s>Transcription factor names and their putative binding sites are shown above and below the corresponding FNTB alleles, respectively.</s><s>C) Genotype-dependent binding of nuclear proteins to the human FNTB promoter as analyzed by EMSA.</s><s>Arrow indicates specifically retarded bands observed upon addition of nuclear extracts.</s><s>A nuclear protein bound the C allele exclusively.</s><s>D) Genotype-dependent activity of FNTB 5'-regulatory region reporter constructs expressed in A2780 and SKOV3 ovarian carcinoma cells.</s><s>E) Relative expression of FNTB mRNA in leukocytes of healthy donors, renal cancer and ovarian cancer tissues dependent on rs11623866 genotypes</s></p></div></figDesc><graphic coords="6,112.54,56.81,369.06,355.47" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3Survival dependent on rs11623866 genotype and treatment arm.</s><s>Kaplan-Meier analysis and the log-rank test were used to calculate survival curves representing progression free (PFS) and overall survival (OS) of 57 patients of the AGO-OVAR-15 study dependent on rs11623866 genotype and treatment arm.</s><s>TC taxane (paclitaxel) + carboplatin ( ); LTC lonafarnib + TC ( )</s></p></div></figDesc><graphic coords="7,112.42,56.81,369.30,205.51" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="5,62.87,338.57,198.91,320.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Baseline characteristics.</s><s>The table summarizes the patients' clinicopathological data and the rs11623866 genotype distribution in the AGO-OVAR-15 subgroup genetics trial, with regard to the lonafarnib treated arm and the non-treated arm</s></p></div></figDesc><table><row><cell></cell><cell>All</cell><cell></cell><cell>TC arm</cell><cell></cell><cell>LTC arm</cell><cell></cell></row><row><cell>Characteristic</cell><cell>n</cell><cell>%</cell><cell>n</cell><cell>%</cell><cell>n</cell><cell>%</cell></row><row><cell cols="3">Number of patients 57 100</cell><cell>27</cell><cell>47.4</cell><cell>30</cell><cell>52.6</cell></row><row><cell>Age (years),</cell><cell cols="3">56 (21-74) 56</cell><cell cols="2">(41-74) 59</cell><cell>(21-71)</cell></row><row><cell>median (range)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Performance status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ECOG 0</cell><cell>28</cell><cell>49.1</cell><cell>13</cell><cell>48.1</cell><cell>15</cell><cell>50.0</cell></row><row><cell>ECOG 1</cell><cell>27</cell><cell>47.4</cell><cell>13</cell><cell>48.1</cell><cell>14</cell><cell>46.7</cell></row><row><cell>ECOG 2</cell><cell>2</cell><cell>3.5</cell><cell>1</cell><cell>3.7</cell><cell>1</cell><cell>3.3</cell></row><row><cell>FIGO stage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IIB-III</cell><cell>47</cell><cell>82.5</cell><cell>23</cell><cell>85.2</cell><cell>24</cell><cell>80.0</cell></row><row><cell>IV</cell><cell>10</cell><cell>17.5</cell><cell>4</cell><cell>14.8</cell><cell>6</cell><cell>20.0</cell></row><row><cell>Histology</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Serous</cell><cell>42</cell><cell>73.7</cell><cell>20</cell><cell>74.1</cell><cell>22</cell><cell>73.3</cell></row><row><cell>Endometroid</cell><cell>4</cell><cell>7.0</cell><cell>3</cell><cell>11.1</cell><cell>1</cell><cell>3.3</cell></row><row><cell>Mucinous</cell><cell>3</cell><cell>5.3</cell><cell>2</cell><cell>7.4</cell><cell>1</cell><cell>3.3</cell></row><row><cell>Other</cell><cell>8</cell><cell>14.0</cell><cell>2</cell><cell>7.4</cell><cell>6</cell><cell>20.0</cell></row><row><cell>Primary tumour</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ovary</cell><cell>52</cell><cell>91.2</cell><cell>23</cell><cell>85.2</cell><cell>29</cell><cell>96.7</cell></row><row><cell>Fallopian tube</cell><cell>0</cell><cell></cell><cell>0</cell><cell></cell><cell>0</cell><cell></cell></row><row><cell>Peritoneum</cell><cell>5</cell><cell>8.8</cell><cell>4</cell><cell>14.8</cell><cell>1</cell><cell>3.3</cell></row><row><cell>Histologic grading</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>G1</cell><cell>2</cell><cell>3.5</cell><cell>0</cell><cell></cell><cell>2</cell><cell>6.7</cell></row><row><cell>G2</cell><cell>20</cell><cell>35.1</cell><cell>12</cell><cell>44.4</cell><cell>8</cell><cell>26.7</cell></row><row><cell>G3</cell><cell>33</cell><cell>57.9</cell><cell>14</cell><cell>51.9</cell><cell>19</cell><cell>63.3</cell></row><row><cell>Unknown</cell><cell>2</cell><cell>3.5</cell><cell>1</cell><cell>3.7</cell><cell>1</cell><cell>3.3</cell></row><row><cell>rs11623866 G &gt; C</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GG</cell><cell>20</cell><cell>35.1</cell><cell>13</cell><cell>48.2</cell><cell>7</cell><cell>23.3</cell></row><row><cell>GC</cell><cell>28</cell><cell>49.1</cell><cell>10</cell><cell>37.0</cell><cell>18</cell><cell>60.0</cell></row><row><cell>CC</cell><cell>9</cell><cell>15.8</cell><cell>4</cell><cell>14.8</cell><cell>5</cell><cell>16.7</cell></row></table><note><p><s>LTC, lonafarnib + TC; TC, taxane (paclitaxel) + carboplatin.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Cox regression analyses.</s><s>The table summarizes results of Cox regression analyses in the AGO-OVAR-15 subgroup genetics trial with regard to rs11623866 genotype, the respective treatment arms and survival (PFS and OS)</s></p></div></figDesc><table><row><cell></cell><cell cols="2">FNTB rs11623866 G &gt; C Genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>GG</cell><cell></cell><cell>GC</cell><cell></cell><cell>CC</cell><cell></cell></row><row><cell></cell><cell>HR (95% CI)</cell><cell>P value</cell><cell>HR (95% CI)</cell><cell>P value</cell><cell>HR (95% CI)</cell><cell>P value</cell></row><row><cell>Progression-free survival</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TC</cell><cell>1</cell><cell></cell><cell>1</cell><cell></cell><cell>1</cell><cell></cell></row><row><cell>LTC</cell><cell>6.242 (2.01, 19.41)</cell><cell>0.002</cell><cell>1.046 (0.44, 2.50)</cell><cell>0.919</cell><cell>1.456 (0.32, 6.62)</cell><cell>0.627</cell></row><row><cell>Overall survival</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TC</cell><cell>1</cell><cell></cell><cell>1</cell><cell></cell><cell>1</cell><cell></cell></row><row><cell>LTC</cell><cell>9.589 (1.89, 48.54)</cell><cell>0.006</cell><cell>1.080 (0.40, 2.91)</cell><cell>0.881</cell><cell>0.474 (0.04, 5.35)</cell><cell>0.546</cell></row><row><cell cols="4">CI, confidence interval; HR, hazard ratio; LTC, lonafarnib + TC; TC, taxane (paclitaxel) + carboplatin.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Br J Clin Pharmacol / 80:5 / 1141</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Br J Clin Pharmacol / 80:5 / 1145</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing Interests</head><p><s>All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no support from any organization for the submitted work.</s></p><p><s>The authors want to thank the AGO study office staff, especially Mrs Gabriele Elser, for administrating our genetic substudy and for coordinating the obtainment of the patients' consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Contributions</head><p><s>The principal investigator is Pauline Wimberger, MD, PhD.</s></p><p><s>HSB, WM, AB, RK, JDK, WS, JS, KW, JH, PH, AB, BS, BA and PW made substantial contributions to the conception and design of the study, to the acquisition data and to analysis/interpretation of the results.</s><s>HSB, PW, WS and JDK designed and performed in vitro analyses and functional assays.</s><s>HSB, PW, WS and JDK were involved in drafting the manuscript or revising it.</s><s>All authors read and approved the manuscript in its final version.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting Information</head><p><s>Additional Supporting Information may be found in the online version of this article at the publisher's web-site:</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table S1</head><p><s>Grading of toxicities by treatment arm Table <ref type="table">S2</ref> Grading of toxicities by treatment arm for FNTB rs11623866 GG genotype carriers</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Parkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1075" to="1107" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<author>
			<persName><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Thigpen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vermorken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Avall-Lundqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bookman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bowtell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Casado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cervantes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Eisenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Friedlaender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fujiwara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grenman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Guastalla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hogberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kitchener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kristensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mannel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Neijt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ozols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Parmar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pecorelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pfisterer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Poveda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Provencher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pujade-Lauraine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Randall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rochon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rustin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sagae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Stehman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stuart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Trimble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vasey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Verheijen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Wagner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference</title>
				<imprint>
			<publisher>GCIG OCCC</publisher>
			<date type="published" when="2004">2004. 2004. 2005</date>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="7" to="12" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d&apos;Investigateurs Nationaux Pour les Etudes des Cancers de l&apos;Ovaire (GINECO)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reuss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pujade-Lauraine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Harter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ray-Coquard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pfisterer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="1234" to="1244" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wimberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lehmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kimmig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schmalfeldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Burges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Harter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pfisterer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1642" to="1648" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Bookman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="87" to="94" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Management of recurrent ovarian carcinoma: current status and future directions</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Schilder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Oncol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="112" to="125" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">A phase 3 trial of bevacizumab in ovarian cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Perren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Swart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pfisterer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Ledermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pujade-Lauraine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kristensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Beale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cervantes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kurzeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sehouli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kimmig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stahle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Collinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Essapen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gourley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lortholary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Selle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Mirza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Leminen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Plante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Stark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Parmar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Oza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="2484" to="2496" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Friedlander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Hancock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rischin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Messing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Stringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Matthys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Hodge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Lager</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="32" to="37" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Basso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mirza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Bishop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kirschmeier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="31101" to="31108" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>Role in FTI enhancement of taxane and tamoxifen anti-tumor activity</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Lipid posttranslational modifications. Farnesyl transferase inhibitors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Basso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kirschmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Bishop</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Lipid Res</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="15" to="31" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hajian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yaremko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lipari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gurnani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Malkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Bishop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="5896" to="5901" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells</title>
		<author>
			<persName><forename type="first">H</forename><surname>Niessner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sinnberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lasithiotakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Maczey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Venturelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mauthe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toulany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Flaherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schaller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schadendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Proikas-Cezanne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schittek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kulms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Meier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="468" to="479" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Marrinan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Nale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Bishop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kirschmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Long</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="97" to="106" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">A phase II study of lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Hanrahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Glisson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Khuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Ginsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Truong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="274" to="279" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Ravoet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mineur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Robin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Debusscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bosly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Housni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Soree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Martiat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="881" to="885" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Winquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Chi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hirte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>North</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Powers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Boucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Patton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Seymour</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urol Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="143" to="149" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kemeny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Kelsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>O'reilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zaknoen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Statkevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hollywood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Saltz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1067" to="1071" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV</title>
		<author>
			<persName><forename type="first">W</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gropp-Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wollschlaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kreienberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Canzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schmalfeldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wimberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Belau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stahle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Burges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sehouli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="236" to="240" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">FNTB polymorphism rs11623866 and the effect of lonafarnib</title>
	</analytic>
	<monogr>
		<title level="j">Br Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="5" to="1147" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kauh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chanel-Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Escuin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Fanucchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Saba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kutner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Ramalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marcus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Giannakakou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Khuri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="4049" to="4059" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Is there a future for prenyltransferase inhibitors in cancer therapy?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Holstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Hohl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="704" to="709" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">FNTB promoter polymorphisms are associated with survival in different cancers</title>
		<author>
			<persName><forename type="first">Hsla</forename><surname>Bachmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Siffert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Naunyn-Schmiedeebergs Arch Pharmacol</title>
		<imprint>
			<biblScope unit="volume">379</biblScope>
			<biblScope unit="page">468</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Die (Weiter-)Verwendung von menschlichen Körpermaterialien von Verstorbenen für Zwecke medizinischer Forschung</title>
	</analytic>
	<monogr>
		<title level="j">Zentrale Ethikkommission bei der Bundesärtzekammer</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page">2251</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Dtsch Arztebl</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">dbSNP: the NCBI database of genetic variation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Sherry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kholodov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Smigielski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sirotkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="308" to="311" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">A map of human genome variation from population-scale sequencing</title>
		<author>
			<persName><forename type="first">Genomes</forename><surname>Project</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Abecasis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Altshuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Auton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Durbin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Gibbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Hurles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Mcvean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">467</biblScope>
			<biblScope unit="page" from="1061" to="1073" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The essence of SNPs</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Brookes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gene</title>
		<imprint>
			<biblScope unit="volume">234</biblScope>
			<biblScope unit="page" from="177" to="186" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Highly specific localization of promoter regions in large genomic sequences by PromoterInspector: a novel context analysis approach</title>
		<author>
			<persName><forename type="first">M</forename><surname>Scherf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Klingenhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Werner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Biol</title>
		<imprint>
			<biblScope unit="volume">297</biblScope>
			<biblScope unit="page" from="599" to="606" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data</title>
		<author>
			<persName><forename type="first">K</forename><surname>Quandt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Frech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Karas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wingender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Werner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="4878" to="4884" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">ConSite: web-based prediction of regulatory elements using cross-species comparison</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sandelin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Wasserman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lenhard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="W249" to="W252" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">AliBaba2: context specific identification of transcription factor binding sites</title>
		<author>
			<persName><forename type="first">N</forename><surname>Grabe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">In Silico Biol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="S1" to="15" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Successful amplification of extremely GC-rich promoter regions using a novel &apos;slowdown PCR&apos; technique</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Bachmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Siffert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">H</forename><surname>Frey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenetics</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="759" to="766" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vandesompele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Preter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pattyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Poppe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Paepe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Speleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Biol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">H0034</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Gaunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Day</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="505" to="514" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant non-small cell lung carcinoma</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">V</forename><surname>Fossella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Glisson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zaknoen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Statkevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Munden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Summey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Pisters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Papadimitrakopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tighiouart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rogatko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Khuri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="561" to="569" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification</title>
		<author>
			<persName><forename type="first">S</forename><surname>Saracchini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Foltran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tuccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bassini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sulfaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Micheli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Conte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bertola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lorenzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tumolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1101" to="1107" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumabbased therapy is offered in the metastatic setting</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Fuchs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Kostler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Horvat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hudelist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kubista</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Attems</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Zielinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Singer</surname></persName>
		</author>
		<idno type="DOI">10.1002/ijc.28660</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="224" to="231" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Treatment of delta hepatitis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Gunsar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Anti Infect Ther</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="489" to="498" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Progeria Clinical Trials C. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Massaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'agostino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Sr</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Brazier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Kleinman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Kieran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="27" to="34" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">An encouraging progress report on the treatment of progeria and its implications for atherogenesis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Oshima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Hisama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="4" to="6" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
